The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L, Hemeryck A, Jacobs S, Baumeister J, Ulrichts H.
Van Roy M, et al. Among authors: hoefman s.
Arthritis Res Ther. 2015 May 20;17(1):135. doi: 10.1186/s13075-015-0651-0.
Arthritis Res Ther. 2015.
PMID: 25994180
Free PMC article.